Evoke Pharma (NASDAQ:EVOK) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Evoke Pharma, Inc. (NASDAQ:EVOK)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $5.59 and traded as low as $5.14. Evoke Pharma shares last traded at $5.53, with a volume of 15,621 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Evoke Pharma in a research note on Saturday. They issued a “sell” rating for the company.

Evoke Pharma Stock Up 3.3 %

The firm’s 50 day simple moving average is $4.81 and its two-hundred day simple moving average is $5.57. The stock has a market capitalization of $47.37 million, a P/E ratio of -3.01 and a beta of 0.39.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.